TD Cowen has adjusted its outlook for Becton, Dickinson and Company (NYSE:BDX), raising its price target to $189 from $183 while reiterating a "hold" rating. This revision follows Becton, Dickinson's robust first-quarter performance, which significantly surpassed analyst expectations. The medical technology firm reported earnings per share of $2.91, exceeding the anticipated $2.81, alongside revenues of $5.25 billion. These figures indicate strong operational execution and market demand for its products. Furthermore, BDX demonstrated proactive capital management, announcing a $10 million share buyback program and tender offers to repurchase up to $1.6 billion in debt. The mixed analyst sentiment reflects the positive financial results balanced against a cautious long-term outlook.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis